Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer

Makito Miyake, Adrienne Lawton, Yunfeng Dai, Myron Chang, Lourdes Mengual, Antonio Alcaraz, Steven Goodison, Charles J. Rosser

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: To determine the diagnostic and prognostic capability of urinary and tumoral syndecan-1 (SDC-1) levels in patients with cancer of the urinary bladder.Methods: SDC-1 levels were quantitated by enzyme-linked immunosorbent assay (ELISA) in 308 subjects (102 cancer subjects and 206 non-cancer subjects) to assess its diagnostic capabilities in voided urine. The performance of SDC-1 was evaluated using the area under the curve of a receiver operating characteristic curve. In addition, immunohistochemical (IHC) staining assessed SDC-1 protein expression in 193 bladder specimens (185 cancer subjects and 8 non-cancer subjects). Outcomes were correlated to SDC-1 levels.Results: Mean urinary levels of SDC-1 did not differ between the cancer subjects and the non-cancer subjects, however, the mean urinary levels of SDC-1 were reduced in high-grade compared to low-grade disease (p < 0.0001), and in muscle invasive bladder cancer (MIBC) compared to non-muscle invasive bladder cancer (NMIBC) (p = 0.005). Correspondingly, preliminary data note a shift from a membranous cellular localization of SDC-1 in normal tissue, low-grade tumors and NMIBC, to a distinctly cytoplasmic localization in high-grade tumors and MIBC was observed in tissue specimens.Conclusion: Alone urinary SDC-1 may not be a diagnostic biomarker for bladder cancer, but its urinary levels and cellular localization were associated with the differentiation status of patients with bladder tumors. Further studies are warranted to define the potential role for SDC-1 in bladder cancer progression.

Original languageEnglish (US)
Article number86
JournalBMC Cancer
Volume14
Issue number1
DOIs
StatePublished - Feb 13 2014

Fingerprint

Syndecan-1
Urinary Bladder Neoplasms
Cytoplasm
Cell Membrane
Neoplasms
Muscles
ROC Curve
Area Under Curve
Urinary Bladder
Biomarkers
Enzyme-Linked Immunosorbent Assay

Keywords

  • Bladder
  • Cancer biomarker
  • Specificity
  • Syndecan

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Miyake, M., Lawton, A., Dai, Y., Chang, M., Mengual, L., Alcaraz, A., ... Rosser, C. J. (2014). Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer, 14(1), [86]. https://doi.org/10.1186/1471-2407-14-86

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. / Miyake, Makito; Lawton, Adrienne; Dai, Yunfeng; Chang, Myron; Mengual, Lourdes; Alcaraz, Antonio; Goodison, Steven; Rosser, Charles J.

In: BMC Cancer, Vol. 14, No. 1, 86, 13.02.2014.

Research output: Contribution to journalArticle

Miyake, Makito ; Lawton, Adrienne ; Dai, Yunfeng ; Chang, Myron ; Mengual, Lourdes ; Alcaraz, Antonio ; Goodison, Steven ; Rosser, Charles J. / Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. In: BMC Cancer. 2014 ; Vol. 14, No. 1.
@article{7ade620904d44f738e730eda5ab4367e,
title = "Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer",
abstract = "Background: To determine the diagnostic and prognostic capability of urinary and tumoral syndecan-1 (SDC-1) levels in patients with cancer of the urinary bladder.Methods: SDC-1 levels were quantitated by enzyme-linked immunosorbent assay (ELISA) in 308 subjects (102 cancer subjects and 206 non-cancer subjects) to assess its diagnostic capabilities in voided urine. The performance of SDC-1 was evaluated using the area under the curve of a receiver operating characteristic curve. In addition, immunohistochemical (IHC) staining assessed SDC-1 protein expression in 193 bladder specimens (185 cancer subjects and 8 non-cancer subjects). Outcomes were correlated to SDC-1 levels.Results: Mean urinary levels of SDC-1 did not differ between the cancer subjects and the non-cancer subjects, however, the mean urinary levels of SDC-1 were reduced in high-grade compared to low-grade disease (p < 0.0001), and in muscle invasive bladder cancer (MIBC) compared to non-muscle invasive bladder cancer (NMIBC) (p = 0.005). Correspondingly, preliminary data note a shift from a membranous cellular localization of SDC-1 in normal tissue, low-grade tumors and NMIBC, to a distinctly cytoplasmic localization in high-grade tumors and MIBC was observed in tissue specimens.Conclusion: Alone urinary SDC-1 may not be a diagnostic biomarker for bladder cancer, but its urinary levels and cellular localization were associated with the differentiation status of patients with bladder tumors. Further studies are warranted to define the potential role for SDC-1 in bladder cancer progression.",
keywords = "Bladder, Cancer biomarker, Specificity, Syndecan",
author = "Makito Miyake and Adrienne Lawton and Yunfeng Dai and Myron Chang and Lourdes Mengual and Antonio Alcaraz and Steven Goodison and Rosser, {Charles J.}",
year = "2014",
month = "2",
day = "13",
doi = "10.1186/1471-2407-14-86",
language = "English (US)",
volume = "14",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer

AU - Miyake, Makito

AU - Lawton, Adrienne

AU - Dai, Yunfeng

AU - Chang, Myron

AU - Mengual, Lourdes

AU - Alcaraz, Antonio

AU - Goodison, Steven

AU - Rosser, Charles J.

PY - 2014/2/13

Y1 - 2014/2/13

N2 - Background: To determine the diagnostic and prognostic capability of urinary and tumoral syndecan-1 (SDC-1) levels in patients with cancer of the urinary bladder.Methods: SDC-1 levels were quantitated by enzyme-linked immunosorbent assay (ELISA) in 308 subjects (102 cancer subjects and 206 non-cancer subjects) to assess its diagnostic capabilities in voided urine. The performance of SDC-1 was evaluated using the area under the curve of a receiver operating characteristic curve. In addition, immunohistochemical (IHC) staining assessed SDC-1 protein expression in 193 bladder specimens (185 cancer subjects and 8 non-cancer subjects). Outcomes were correlated to SDC-1 levels.Results: Mean urinary levels of SDC-1 did not differ between the cancer subjects and the non-cancer subjects, however, the mean urinary levels of SDC-1 were reduced in high-grade compared to low-grade disease (p < 0.0001), and in muscle invasive bladder cancer (MIBC) compared to non-muscle invasive bladder cancer (NMIBC) (p = 0.005). Correspondingly, preliminary data note a shift from a membranous cellular localization of SDC-1 in normal tissue, low-grade tumors and NMIBC, to a distinctly cytoplasmic localization in high-grade tumors and MIBC was observed in tissue specimens.Conclusion: Alone urinary SDC-1 may not be a diagnostic biomarker for bladder cancer, but its urinary levels and cellular localization were associated with the differentiation status of patients with bladder tumors. Further studies are warranted to define the potential role for SDC-1 in bladder cancer progression.

AB - Background: To determine the diagnostic and prognostic capability of urinary and tumoral syndecan-1 (SDC-1) levels in patients with cancer of the urinary bladder.Methods: SDC-1 levels were quantitated by enzyme-linked immunosorbent assay (ELISA) in 308 subjects (102 cancer subjects and 206 non-cancer subjects) to assess its diagnostic capabilities in voided urine. The performance of SDC-1 was evaluated using the area under the curve of a receiver operating characteristic curve. In addition, immunohistochemical (IHC) staining assessed SDC-1 protein expression in 193 bladder specimens (185 cancer subjects and 8 non-cancer subjects). Outcomes were correlated to SDC-1 levels.Results: Mean urinary levels of SDC-1 did not differ between the cancer subjects and the non-cancer subjects, however, the mean urinary levels of SDC-1 were reduced in high-grade compared to low-grade disease (p < 0.0001), and in muscle invasive bladder cancer (MIBC) compared to non-muscle invasive bladder cancer (NMIBC) (p = 0.005). Correspondingly, preliminary data note a shift from a membranous cellular localization of SDC-1 in normal tissue, low-grade tumors and NMIBC, to a distinctly cytoplasmic localization in high-grade tumors and MIBC was observed in tissue specimens.Conclusion: Alone urinary SDC-1 may not be a diagnostic biomarker for bladder cancer, but its urinary levels and cellular localization were associated with the differentiation status of patients with bladder tumors. Further studies are warranted to define the potential role for SDC-1 in bladder cancer progression.

KW - Bladder

KW - Cancer biomarker

KW - Specificity

KW - Syndecan

UR - http://www.scopus.com/inward/record.url?scp=84893673424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893673424&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-14-86

DO - 10.1186/1471-2407-14-86

M3 - Article

VL - 14

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 86

ER -